Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.

Background: Treatment of patients with membranous glomerulonephritis (MGN) is controversial because of the lack of clear benefit of the immunosuppressive regimens on patient or renal survival. The objective of this study is to evaluate the efficacy and safety of mycophenolate mofetil (MMF) for patients with MGN.

Study Design: 1-year prospective, randomized, and controlled clinical trial.